文献速递肾小球疾病

PODO试验设计:PF-06730512治疗局灶节段性肾小球硬化的2期研究

PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis.
PubMed 文献 · Kidney Int Rep · 2021-04-03

PODO是一项开放标签、2a期、多中心试验,评估ROBO2融合蛋白PF-06730512在成人FSGS患者中的初步疗效与安全性。患者分高、低剂量两组(每组n=22),每2周静脉给药一次,持续12周,主要终点为第13周UPCR较基线变化。

要点

  • PF-06730512抑制ROBO2/SLIT2信号,旨在稳定足细胞黏附并减少蛋白尿。
  • 纳入经活检确诊FSGS、eGFR≥45(近期活检可30-45)、UPCR>1.5 g/g的成人。
  • 主要终点为第13周UPCR较基线变化,次要终点包括安全性和eGFR变化。

核心结论

  • 这项概念验证研究的结果可能支持PF-06730512治疗FSGS的进一步开发,并值得在3期临床试验中评估。

研究设计与样本

  • PODO(NCT03448692)为开放标签、2a期、多中心试验,在成人FSGS患者中分2个队列(每组n=22),分别接受高或低剂量PF-06730512静脉给药,每2周一次,持续12周。

主要发现

  • 该试验正在进行中,将报告PF-06730512在FSGS患者中的疗效、安全性、药代动力学和生物标志物结果。

关键数值与推荐

  • 关键纳入标准包括经活检确诊FSGS、基于CKD-EPI公式的eGFR≥45 ml/min/1.73 m2(近期活检者可为30-45)、UPCR>1.5 g/g。
  • 关键排除标准包括塌陷型FSGS、严重或活动性感染、活检显示≥50%肾小管间质纤维化以及器官移植。
  • 主要终点为第13周UPCR较基线的变化;次要终点包括安全性、eGFR变化和PF-06730512血清浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Focal segmental glomerulosclerosis (FSGS) is characterized by proteinuria and a histologic pattern of glomerular lesions of diverse etiology that share features including glomerular scarring and podocyte foot process effacement. Roundabout guidance receptor 2 (ROBO2)/slit guidance ligand 2 (SLIT2) signaling destabilizes the slit diaphragm and reduces podocyte adhesion to the glomerular basement membrane (GBM). Preclinical studies suggest that inhibition of glomerular ROBO2/SLIT2 signaling can stabilize podocyte adhesion and reduce proteinuria. This clinical trial evaluates the preliminary efficacy and safety of ROBO2/SLIT2 inhibition with the ROBO2 fusion protein PF-06730512 in patients with FSGS. METHODS: The Study to Evaluate PF-06730512 in Adults With FSGS (PODO; ClinicalTrials.gov identifier NCT03448692), an open-label, phase 2a, multicenter trial in adults with FSGS, will enroll patients into 2 cohorts (n = 22 per cohort) to receive either high- or low-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks. Key inclusion criteria include a confirmed biopsy diagnosis of FSGS, an estimated glomerular filtration rate (eGFR) ≥45 ml/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration formula (30-45 with a recent biopsy), and urinary protein-to-creatinine ratio (UPCR) >1.5 g/g. Key exclusion criteria include collapsing FSGS, serious/active infection, ≥50% tubulointerstitial fibrosis on biopsy, and organ transplantation. The primary endpoint is change from baseline to week 13 in UPCR; secondary endpoints include safety, changes in eGFR, and PF-06730512 serum concentration. RESULTS: This ongoing trial will report the efficacy, safety, pharmacokinetics, and biomarker results of PF-06730512 for patients with FSGS. CONCLUSION: Findings from this proof-of-concept study may support further development and evaluation of PF-06730512 to treat FSGS and warrant assessment in phase 3 clinical trials.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Beck LH, Berasi SP, Copley JB, et al. PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2021. PMID: 34169203. doi:10.1016/j.ekir.2021.03.892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。